Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Accumulated Expenses: 2017-2025

Historic Accumulated Expenses for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $37.1 million.

  • Puma Biotechnology's Accumulated Expenses fell 26.74% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year decrease of 26.74%. This contributed to the annual value of $36.9 million for FY2024, which is 30.01% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Accumulated Expenses is $37.1 million, which was up 16.73% from $31.8 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Accumulated Expenses ranged from a high of $92.6 million in Q4 2021 and a low of $26.9 million during Q1 2025.
  • For the 3-year period, Puma Biotechnology's Accumulated Expenses averaged around $37.8 million, with its median value being $36.9 million (2024).
  • In the last 5 years, Puma Biotechnology's Accumulated Expenses soared by 50.96% in 2021 and then slumped by 56.28% in 2022.
  • Over the past 5 years, Puma Biotechnology's Accumulated Expenses (Quarterly) stood at $92.6 million in 2021, then crashed by 42.71% to $53.0 million in 2022, then fell by 0.59% to $52.7 million in 2023, then tumbled by 30.01% to $36.9 million in 2024, then dropped by 26.74% to $37.1 million in 2025.
  • Its Accumulated Expenses stands at $37.1 million for Q3 2025, versus $31.8 million for Q2 2025 and $26.9 million for Q1 2025.